Literature DB >> 24501341

Immune responses of Iranian patients with visceral leishmaniasis and recovered individuals to LCR1 of Leishmania infantum.

Hamid M Niknam1, Firoozeh Abrishami, Mohammad Doroudian, Mosayeb Rostamian, Maryam Moradi, Vahid Khaze, Davood Iravani.   

Abstract

Visceral leishmaniasis is a serious public health problem. Leishmania infantum is one of its causative agents. LCR1 is an immunogen from L. infantum. Antibodies against this protein have been detected in visceral leishmaniasis patients. The aim of this study was to define the antibody and cellular immune responses against LCR1 in Iranian visceral leishmaniasis patients and recovered individuals. The LCR1 protein was produced in recombinant form. Antibody responses against this protein were studied in Iranian individuals with a recent history of visceral leishmaniasis. Responses of peripheral blood mononuclear cells to this protein were studied in Iranian individuals who had recovered from visceral leishmaniasis. Our data show that (i) there was an antibody response to LCR1 in each individual with a recent history of visceral leishmaniasis studied, (ii) there was neither a proliferative response nor production of gamma interferon (IFN-γ) or interleukin 10 in response to LCR1 by mononuclear cells from individuals who had recovered from visceral leishmaniasis, and (iii) individuals who have recovered from visceral leishmaniasis show ongoing immune responses long after recovery from the disease. These data show that there are no detectable cellular memory responses to LCR1 in Iranian individuals who have recovered from visceral leishmaniasis, while there are detectable antibody responses in patients with this disease. Our data suggest that LCR1 has potential applications for the diagnosis of leishmaniasis through antibody detection, while the application of LCR1 alone for induction of IFN-γ in individuals who recovered from this disease is not supported. The presence of long-lasting immune reactivities in individuals who recovered from the disease may show the necessity of extended medical surveillance for these individuals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24501341      PMCID: PMC3993108          DOI: 10.1128/CVI.00711-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  15 in total

Review 1.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

2.  Phytomitogen responses of peripheral blood lymphocytes in young and older subjects.

Authors:  B S Foad; L E Adams; Y Yamauchi; A Litwin
Journal:  Clin Exp Immunol       Date:  1974-08       Impact factor: 4.330

3.  Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.

Authors:  Eszter Deak; Asha Jayakumar; Ka Wing Cho; Karen Goldsmith-Pestana; Blaise Dondji; John D Lambris; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

Review 4.  Immune responses in kala-azar.

Authors:  Samiran Saha; Smriti Mondal; Antara Banerjee; Jayeeta Ghose; Sudipta Bhowmick; Nahid Ali
Journal:  Indian J Med Res       Date:  2006-03       Impact factor: 2.375

5.  Leishmaniasis in Sudan. Visceral leishmaniasis.

Authors:  E E Zijlstra; A M el-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2001-04       Impact factor: 2.184

6.  B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology.

Authors:  S C Smelt; S E Cotterell; C R Engwerda; P M Kaye
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

7.  Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.

Authors:  S Gillis; R Kozak; M Durante; M E Weksler
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

8.  Cytokine profile and pathology in human leishmaniasis.

Authors:  A Ribeiro-de-Jesus; R P Almeida; H Lessa; O Bacellar; E M Carvalho
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

9.  Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi.

Authors:  E M Carvalho; A Barral; D Pedral-Sampaio; M Barral-Netto; R Badaró; H Rocha; W D Johnson
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

10.  Impaired lymphocyte function in aged humans.

Authors:  M E Weksler; T H Hütteroth
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.